AbbVie News Center - News
5 days ago · AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics. Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer NORTH CHICAGO,... All News.
AbbVie to Acquire ImmunoGen, including its Flagship Cancer
Nov 30, 2023 · The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space. Additionally, ImmunoGen's follow-on pipeline of promising next-generation ADCs further complements AbbVie's ADC platform and existing programs.
AbbVie to Acquire Cerevel Therapeutics in Transformative ... - News
Dec 6, 2023 · Cerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipeline. Emraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditions. Transaction valued at $45.00 per share in cash, for a total equity value of approximately $8.7 billion.
AbbVie Completes Acquisition of ImmunoGen - Feb 12, 2024
Feb 12, 2024 · AbbVie expects its acquisition of ImmunoGen to be accretive to AbbVie's diluted EPS beginning in 2027 and significantly accretive over the long-term. Full-Year 2024 Outlook. AbbVie is reaffirming its previously issued 2024 full-year …
AbbVie to Acquire Landos Biopharma, Further Strengthening its
Mar 25, 2024 · NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 / PRNewswire / -- AbbVie Inc. (NYSE: ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients ...
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
Feb 2, 2024 · Reports Fourth-Quarter Diluted EPS of $0.46 on a GAAP Basis, a Decrease of 66.7 Percent; Adjusted Diluted EPS of $2.79, a Decrease of 22.5 Percent; These Results Include an Unfavorable Impact of $0.15 Per Share Related to Fourth-Quarter 2023 Acquired IPR&D and Milestones Expense.
AbbVie Completes Acquisition of Cerevel Therapeutics
Aug 1, 2024 · AbbVie Completes Acquisition of Cerevel Therapeutics. Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's disease.
AbbVie Announces Appointment of Robert A. Michael as Chief …
Feb 20, 2024 · Richard A. Gonzalez to retire as AbbVie CEO to become Executive Chairman. Transition will occur on July 1, 2024. NORTH CHICAGO, Ill., Feb. 20, 2024 / PRNewswire / -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously selected Robert A. Michael, AbbVie's current president and chief operating officer, to succeed ...
AbbVie Announces Positive Topline Results from Phase 2 ... - News
NORTH CHICAGO, Ill., Nov. 29, 2023 / PRNewswire / -- AbbVie (NYSE: ABBV) announced today topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung ...
U.S. Food and Drug Administration (FDA) Grants ... - AbbVie News …
NORTH CHICAGO, Ill., March 22, 2024 / PRNewswire / -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for ELAHERE® (mirvetuximab soravtansine-gynx) for the treatment of folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary ...